Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on dyslipidemia.

Abhimanyu Garg1, Vinaya Simha

  • 1Division of Nutrition and Metabolic Diseases, Center for Human Nutrition, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390-9052, USA. abhimanyu.garg@utsouthwestern.edu

The Journal of Clinical Endocrinology and Metabolism
|May 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safe Use of Metformin in Mitochondrial Diabetes: Response to Letter to Editor.

AACE endocrinology and diabetes·2026
Same author

Familial Generalized and Partial Lipodystrophies Due to Rare Biallelic Variants in <i>LMNA</i>.

International journal of molecular sciences·2026
Same author

Genotype-Phenotype Heterogeneity Among Patients with Lipodystrophy Harboring Rare POLD1 Variants.

The Journal of clinical endocrinology and metabolism·2026
Same author

Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor-induced Lipodystrophy.

JCEM case reports·2026
Same author

Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.

International journal of molecular sciences·2026
Same author

Response to letter to the editor by Matsubara and colleagues.

Journal of clinical lipidology·2026
Same journal

Continuous glucose monitoring-derived time in range is associated with changes in arterial stiffness in type 2 diabetes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Association of the Primary Aldosteronism Severity Classification with Lateralization and Treatment Outcomes.

The Journal of clinical endocrinology and metabolism·2026
Same journal

From Premature Adrenarche to Adult Metabolic Risk and Hyperandrogenism: A Systematic Review and Meta-Analysis.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency.

The Journal of clinical endocrinology and metabolism·2026
Same journal

Correction to: "CAHQL: A Patient-Reported Outcome Instrument to Assess Health-Related Quality of Life in Congenital Adrenal Hyperplasia".

The Journal of clinical endocrinology and metabolism·2026
Same journal

Approach to Personalizing the Treatment of Osteoporosis.

The Journal of clinical endocrinology and metabolism·2026
See all related articles

Recent advances identify genetic causes of dyslipidemias and evaluate lipid-lowering drugs for coronary heart disease (CHD) prevention. Understanding the risk-benefit of intensive statin therapy and exploring alternative treatments like fibrates are crucial for managing high cholesterol.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Significant progress in understanding the genetic underpinnings of dyslipidemias.
  • Identification of novel genetic loci associated with monogenic hypercholesterolemia, including LDLR-associated protein, PCSK9, and ABCG5/ABCG8.
  • Linkage of familial hypertriglyceridemia to apolipoprotein AV, with ongoing debate regarding familial combined hyperlipidemia and USF1.

Purpose of the Study:

  • To review recent advancements in the genetic basis of dyslipidemias.
  • To evaluate the safety and efficacy of lipid-lowering drugs for coronary heart disease (CHD) prevention.
  • To discuss current guidelines and the risk-benefit profile of intensive statin therapy.

Main Methods:

  • Review of recent genetic discoveries for dyslipidemias.

Related Experiment Videos

  • Analysis of clinical trial data on statin therapy for CHD prevention.
  • Evaluation of dietary interventions and fibrate therapy for lipid management.

    • Main Results:

    • Novel genes identified for hypercholesterolemia and hypertriglyceridemia.
    • Adult Treatment Panel III guidelines emphasize intensive LDL cholesterol reduction.
    • Mixed results from high- vs. low-dose statin trials; potential risks of myopathy and hepatotoxicity with intensive therapy.

    Conclusions:

    • Dietary modifications and soluble fiber can lower LDL cholesterol.
    • Fibrates may reduce pancreatitis risk and offer CHD benefits, but combined therapy with statins requires further investigation.
    • Individualized risk-benefit assessment is essential for intensive statin therapy due to potential adverse effects.